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Interleukin-6 (IL-6) and IL-27 signal through a shared
receptor subunit and employ the same downstream
STAT transcription proteins, but yet are ascribed
unique and overlapping functions. To evaluate the
specificity and redundancy for these cytokines, we
quantified their global transcriptomic changes and
determined the relative contributions of STAT1 and
STAT3 using geneticmodels and chromatin immuno-
precipitation-sequencing (ChIP-seq) approaches.
We found an extensive overlap of the transcriptomes
induced by IL-6 and IL-27 and few examples in which
the cytokines acted in opposition. Using STAT-defi-
cient cells and T cells from patients with gain-of-
function STAT1 mutations, we demonstrated that
STAT3 is responsible for the overall transcriptional
output driven by both cytokines, whereas STAT1 is
the principal driver of specificity. STAT1 cannot
compensate in the absence of STAT3 and, in fact,
much of STAT1 binding to chromatin is STAT3
dependent. Thus, STAT1 shapes the specific cyto-
kine signature superimposed upon STAT3’s action.
INTRODUCTION
Cytokines are a diverse group of factors that regulate hemato-
poiesis and host defense, as well as homeostasis, metabolism,and growth. Despite many distinct activities, widespread func-
tional redundancy is an unforeseen aspect of cytokine biology,
and a critical departure from the ‘‘one cytokine one function’’
theme that dominated in early cytokine research (Paul, 1989).
However, the advent of cytokine- and cytokine-receptor-
deficient mice has emphasized non-redundant functionalities,
as manifested by distinct in vivo phenotypes. Reconciling
specificity in the context of redundancy and deciphering the
molecular underpinning for both functional aspects has been a
longstanding conundrum in cytokine biology.
Interleukin-27 (IL-27) was first recognized to induce interferon
(IFN)-g, T-bet, and IL-12Rb2 (Hibbert et al., 2003; Pflanz et al.,
2002). However, mice lacking IL-27 responsiveness clearly
demonstrate that the essential, non-redundant function of IL-
27 is constraining immune responses (Villarino et al., 2003).
The mechanisms underlying IL-27’s immunosuppressive as-
pects include inhibition of IL-17, the transcription factors RORgt,
RORa, GATA-3, and the growth and differentiation factor GM-
CSF (Diveu et al., 2009; Lucas et al., 2003; Stumhofer et al.,
2006; Young et al., 2012). IL-27 also induces PD-L1 (Hirahara
et al., 2012), IL-10 (Awasthi et al., 2007; Stumhofer et al.,
2007), and promotes the differentiation of T regulatory 1 (Tr1)
cells (Apetoh et al., 2010; Awasthi et al., 2007). Il27 polymor-
phisms with chronic obstructive pulmonary disease, inflamma-
tory bowel disease, and diabetes (Barrett et al., 2009; Huang
et al., 2008; Imielinski et al., 2009) also support immunoregula-
tory roles.
IL-27 binds to a receptor composed of a ligand-specific sub-
unit, termed WSX-1, and glycoprotein 130 (GP130) (Pflanz
et al., 2004). GP130 is a shared signaling subunit also used by
IL-6 (Taga et al., 1989). This is notable since IL-6 and IL-27Immunity 42, 877–889, May 19, 2015 ª2015 Elsevier Inc. 877
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have been characterized as have opposing functions: IL-6 in-
hibits T helper 1 (Th1) cell differentiation, enhances Th2 cell
differentiation and promotes Th17 cell differentiation, whereas
IL-27 promotes Th1 cell differentiation and inhibits both Th2
and Th17 cell differentiation (Bettelli et al., 2006; Diehl et al.,
2000; Rinco´n et al., 1997). Like other members of the hemato-
poietin family of receptors, IL-27 and IL-6 exert their effect
through Janus kinases and signal transducer and activator of
transcription (STATs), mainly via a combination of STAT3 and
STAT1 (Lucas et al., 2003; Takeda et al., 2003; Villarino et al.,
2003). The pro-inflammatory actions of IL-6 have been attributed
to STAT3, whereas the ability to activate STAT1 has been argued
to explain the ‘‘Th1’’ cell features of IL-27, as well as its ability to
inhibit Th17 cells (Villarino et al., 2010). However, immunosup-
pressive functions of IL-27 have also been attributed to STAT3
(Pot et al., 2011). The ability of both cytokines to activate both
STATs seems paradoxical given their distinct functions and it re-
mains unclear how STAT3, for example, can support both the
immunosuppressive actions of IL-27 and the proinflammatory
effects of IL-6.
Because of the distinct functions of IL-6 and IL-27 in the
context of shared signaling mechanisms, we investigated the
questions of cytokine redundancy and specificity in this system.
Using genome-wide approaches that permit comprehensive,
quantitative analyses, we found that IL-6 and IL-27 regulated
many of the same genes, but despite the commonalities in
signal transduction, also had discrete transcriptomic profiles.
Mechanistically, we found that STAT3 controlled the overall
magnitude of transcriptional outputs driven by IL-6 and IL-27
while STAT1 diversified their transcriptional responses. STAT1
did not compensate for STAT3 on a genomic level and
most STAT1 binding to chromatin was dependent on the avail-
ability of STAT3. Rather, STAT1 drove the distinct effects of
these cytokines, as evidenced by T cells from STAT1-deficient
mice and also from patients with STAT1 gain-of-function muta-
tions. Thus, STAT3 is fundamental for both IL-6 and IL-27
response whereas STAT1 serves to shape unique cytokine
signatures.
RESULTS
IL-6- and IL-27- Transcriptomes Exhibit Considerable
Overlap
To explore the unique and redundant functions of IL-6 and IL-27,
we sought to define global transcriptional changes using acti-
vated CD4+ helper T cells as a model system. First we confirmedFigure 1. Quantitation and Analysis of IL-6 and IL-27 Transcriptomic R
Naive CD4+ T cells were cultured for 3 days on anti-CD3- and anti-CD28-coated p
as RPKM (reads per kilobase exon per million mapped reads).
(A) Gene expression changes of >2 fold or <0.5 fold by IL-6 or IL-27 compared to c
and clustered based on their selective regulation by IL-6 (IL-6 unique), IL-27 (IL-
oppositely regulated by IL-6 and IL-27, is denoted by the asterisk and highlighte
(C and D) GSEA for IL-6- or IL-27-regulated genes are compared to genes expre
upregulated, IL-6 downregulated, and IL-27 downregulated genes are plotted se
regulated genes versus Th1 or Th2 cell-associated genes (FDR, false discovery
(E) IL-6 and IL-27 dependency of representative Th1 and Th2 cell-associated ge
(F and G) GSEA for IL-6 or IL-27 regulated-gene sets plotted against genes expr
(H) IL-6 and IL-27 dependency of representative Th17- and iTreg cell-expresse
average of the two was used for all downstream analyses presented in Figures 1that activated T cells express receptors for both cytokines (Fig-
ure S1A), and then measured gene expression by RNA-seq in
response to exogenous IL-6 or IL-27 using activated untreated
(i.e., no added cytokines) cells as a control.
We found that IL-6 induced 481 genes and repressed 401
genes (>2 fold change), whereas IL-27 induced 331 genes and
repressed 359 genes (Figure 1A and S1B). More than half
(n = 503) of IL-6-regulated genes (n = 882) were unique to this
cytokine (Figure 1A) and 311 of 690 IL-27-regulated genes
were selectively regulated by IL-27 (Figure 1A). Thus, the propor-
tion of genes commonly regulated by IL-6 and IL-27 was roughly
equivalent to the uniquely regulated genes.
Considering the opposing biological functions of these two
cytokines, we expected that a substantial subset of genes would
be oppositely regulated. However, only a very small proportion
of genes (22 genes) were oppositely regulated by IL-6 and IL-
27 (Figures 1A, asterisk, and 1B). Nonetheless their identity
was noteworthy; they included key immunoregulatory factors,
such as Ifng, Ccl5, and Rorc (Figure 1B).
The opposing regulation of Ifng by IL-27 and IL-6 was notable
in view of the reported effects of IL-27 and IL-6 as ‘‘Th1’’ and
‘‘Th2’’ cell-associated cytokines, respectively (Rinco´n et al.,
1997). Therefore, we compared the transcriptional signature of
IL-6 and IL-27 to gene-expression profiles of canonical helper
T cell subsets (Figures 1C to 1H). Both IL-6 and IL-27 contributed
similarly to Th1 versus Th2 cell-associated transcriptional signa-
tures (Figures 1C and 1D). In fact, closer examination of individ-
ual ‘‘Th1 or Th2’’ cell-associated genes revealed variegated
patterns (Figure 1E).
The immunoregulatory actions of IL-6 and IL-27 also relate to
their effects on promoting or inhibiting immune responses
(Hunter and Kastelein, 2012; Korn et al., 2009). Therefore, we
compared the IL-6- and IL-27-regulated genes to programs
associated with Th17 or inducible T regulatory (iTreg) cells. There
was little global distinction between IL-6 and IL-27 with respect
to the spectrum of gene-expression characteristic of Th17 or
iTreg cells (Figures 1F and 1G). IL-6 and IL-27 elicited similar,
as well as opposing, effects on key genes (Figure 1H). Taken
together, our comparative transcriptomic analyses revealed a
degree of redundancy in gene sets regulated by IL-6 and IL-
27, but also identified several key genes that did not conform
to the expected general trend of coordinated regulation elicited
by these two cytokines. Thus, the actions of IL-6 and IL-27 on
T cells are sui generis; trying to categorize them as ‘‘Th1 cell-
like,’’ Th2 cell-like,’’ and pro- or anti-inflammatory is overly
simplistic and belies important aspects of their function.esponses
lates with or without IL-6 or IL-27. Gene expression wasmeasured by RNA-seq
ells cultured without exogenous cytokines (n = 1,193) are depicted by heatmap
27 unique), or both cytokines (common). The small subset of atypical genes,
d in (B).
ssed in Th1 and Th2 cells (data from GEO GSE45975). IL-6 upregulated, IL-27
parately, and each analysis shows non-random distribution of IL-6- or IL-27-
rate; NES, normalized enrichment score).
nes identified by GSEA analysis in C and D are shown.
essed in Th17 and iTreg cells (data from GEO GSE45975).
d genes. The RNA-seq data were acquired as biological duplicates, and the
, 3, 4, and 5. See also Figure S1.
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Figure 2. The Ability of IL-6 and IL-27 to
Access STAT1 and STAT3 Dynamically
Changes with T Cell Activation
(A–F) Sorted naive CD4+ T cells were stimulated
with anti-CD3 and anti-CCD28 with or without the
indicated cytokines for 3 days (A). With indicated
stimulation and time points, STAT1 and STAT3
protein amounts were measured by immunoblot-
ting (B and C), intracellular staining and flow cy-
tometry (phospho-STATs) (D), and EMSA (E and F).
(C) Pooled data from four independent experi-
ments are provided (mean ± SD, p value by un-
paired Student’s t test, ***p < 0.001, **p < 0.01, NS,
not significant). (D) Time course of STAT1 and
STAT3 phosphorylation following cytokine stimu-
lation was evaluated for up to 72 hr. (E) The
positions of STAT1-STAT1, STAT1-STAT3, and
STAT3-STAT3 dimers are indicated. (F) The in-
tensity of STAT3-STAT3, STAT3-STAT1, and
STAT1-STAT1dimer species in (E)wasquantitated
by densitometry. See also Figure S2.IL-27 and IL-6 Dynamically Activate STAT1 and STAT3
IL-27 and IL-6 employ multiple STATs, but are most associated
with STAT1 and STAT3 (Lucas et al., 2003; Takeda et al., 1998;
Villarino et al., 2003). However, it is known that expression
of STAT proteins is dynamic (Gil et al., 2012). Therefore,
we measured expression of STAT1 and STAT3 and found
that both were induced in anti-CD3- and anti-CD28-
activated CD4+ T cells, but the inclusion of IL-6 or IL-27 in
cultures did not alter expression further (Figures 2A to
2C). In terms of STAT activity, IL-27 induced phosphoryla-
tion of STAT1 and STAT3 with the former being more
prominent (Figures S2A to S2C). IL-6 also induced robust
phosphorylation of both. Under the conditions employed, IL-
27 and IL-6 did not enhance phosphorylation of other STATs880 Immunity 42, 877–889, May 19, 2015 ª2015 Elsevier Inc.beyond what was seen in untreated cells
(Figures S2B and S2C).
Next, we evaluated the dynamics of
STAT activation by flow cytometry and
found that IL-27 and IL-6 initially acti-
vated STAT1 to comparable amounts.
Over the course of 72 hr, IL-6-mediated
STAT1 activation declined but IL-27-
dependent STAT1 activation increased
(Figure 2D, left panel). IL-6 initially acti-
vated STAT3 more than IL-27 but at later
time points, IL-27 activated STAT3 more
than IL-6 (Figure 2D, right panel). In the
absence of STAT3, STAT1 activation
was increased but without STAT1,
STAT3 activation was unchanged.
We also measured STAT activation
by electrophoretic mobility shift assay
(EMSA) (Figures 2E and 2F). At 24 hr
post-stimulation, IL-27 induced roughly
equivalent amounts of STAT1 and
STAT3 homodimers, and STAT1-STAT3
heterodimers. IL-6 induced more STAT3
homodimers and STAT1-STAT3 hetero-dimers but little STAT1 homodimers. These data are consistent
with the notion that IL-27 and IL-6 each employ STAT1 and
STAT3 and also suggest that duration, intensity, and dimer
composition of STAT activities are dynamically regulated by
the two cytokines.
We also tested the potential contribution of other signaling
pathways that included AKT, ERK1, ERK2, IRS-1, GSK-3A,
and GSK-3B (Figure S2D), but found no significant differences
between IL-6 and IL-27 in our experimental system.
STAT3 Regulates the Transcriptional Outputs of IL-6
and IL-27
To determine the functional contribution of STAT1 and STAT3
for IL-6 and IL-27, we assessed the transcriptomic impact of
STAT-deficiency. For genes selectively controlled by IL-6, regu-
lation was profoundly affected by the absence of STAT3 (>90%);
a much smaller proportion (20.3%) was STAT1-dependent (Fig-
ure 3A, 3B, 3H, and S3A). For genes commonly regulated by IL-6
and IL-27, the influence of STAT3was still dominant (74.9%) over
that of STAT1 (20.6%) (Figures 3C, 3D, and 3H). For genes selec-
tively regulated by IL-27, the contribution of STAT1 was more
prominent (65.0%), although the influence of STAT3 was still
profound (76.8%) (Figures 3E–3H). Only 42 genes (13.5%)
were strictly STAT1-dependent and 79 genes (25.4%) were
completely STAT3-dependent (Figure 3G). These data reveal a
broad contribution of STAT3 to the overall transcriptional output
of both IL-6 and IL-27, indicating that STAT1 cannot compensate
in the absence of STAT3. Representative examples are shown in
Figure S3B.
STAT1 Drives the Specificity of IL-27 versus IL-6
Next, we focused on the role of STAT1 on the transcription pro-
grams.We found thatmost IL-6 unique and common geneswere
preserved in the absence of STAT1 (Figures 3A and 3C). In the
absence of STAT1, however, the genes regulated by IL-6 or IL-
27 largely overlapped (726 genes of 811 genes; 89.5%), indi-
cating a loss of cytokine specificity (Figure 4A, right panel).
Furthermore, consistent with a previous report (Gil et al., 2001),
the absence of STAT1 resulted in a gain-of-function phenotype
such that IL-6 and IL-27 induced 1,741 de novo genes that
were not normally seen in wild-type (Figure 4B). Overall, 2,552
genes were regulated by IL-6 and IL-27 in STAT1 deleted cells,
and cytokine response of these genes was highly correlated
between IL-6 and IL-27 (r = 0.9823, Pearson’s coefficient)
compared with that of wild-type (r = 0.6482) (Figure 4C). This
was not the case with cells lacking STAT3 in which very few de
novo genes were observed (Figure S4A) and cytokine specificity
was maintained (Figure S4B).
Asymmetric Roles of STAT3 and STAT1 in
Transcriptomic Responses
RNA-seq analysis of STAT-deficient cells argued that STAT1 and
STAT3 fundamentally differ in their ability to affect transcriptional
programs. To further explore this issue, we analyzed three cate-
gories of genes in terms of cytokine response (IL-6 unique, com-
mon, IL-27 unique) and assessed the fate of individual genes in
STAT-deficient cells (Figures 5A and 5B). The major conse-
quence of STAT1 deficiency was an expansion of genes co-
regulated by IL-6 and IL-27 (Figure 5A, right side), whereas
STAT3 deficiency was associated with the loss of overall cyto-
kine response in all categories (Figure 5B, right side). The re-
maining genes were mainly IL-27-specific because they retained
their original specificity or acquired an aberrant, new ‘‘specific’’
response (Figure 5B). Therefore, when all IL-6 and IL-27 respon-
sive genes (1,193 genes in total) were evaluated in detail, we
observed stark contrast between STAT3 and STAT1 regarding
their global impact on cytokine specificity versus transcriptional
output. A similar result was obtained when the expression of all
genes was assessed (Figure 5C). Clear separation of clusters
was evident corresponding to the three genotypes used (wild-
type, Stat1/, Stat3/). In wild-type cells, the transcriptomes
of IL-27- and IL-6-treated cells were distinct from each other
and untreated cells. The separation between IL-6- and IL-27-stimulated cells was lost in the Stat1/ cells, but there was still
separation from untreated cells. In the Stat3/ cells, all distinc-
tion was lost, as evidenced by the convergence of the untreated,
IL-6, and IL-27 groups within this cluster.
We next evaluated the impact of STAT deficiency on transcrip-
tomic changes over time (Figure 5D). At very early time points
after stimulation (6 hr), loss of STAT1 had relatively little effect
on IL-6-unique genes, with a greater effect on IL-27-unique
genes. Over time, the transcriptomes induced by IL-6 and IL-
27 expanded in wild-type and the loss of transcriptome output
associated with STAT3 deficiency becamemore profound. Simi-
larly, the expansion of common genes was more apparent in
STAT1-deficient cells at later time points. Presumably, this rep-
resents the integration of direct and indirect effects of autocrine
cytokines, but regardless, the distinctive functions of STAT1 and
STAT3 are very evident.
STAT1 and STAT3 Dynamically Bind to Chromatin in an
Asymmetric Fashion
We next assessed how genome-wide STAT3 and STAT1 distri-
bution relates to the transcriptional activities of IL-27 and IL-6.
Using STAT ChIP-seq, we found that some STAT1 and STAT3
peaks were stable, but cytokines markedly induced the genomic
occupancy of both STATs (Figures 6A and 6B). A fraction of
peaks were lost after cytokine stimulation. These data empha-
size the contribution of STAT1 and STAT3 to the responses of
both cytokines (Figure 6B). Canonical STAT binding motif (i.e.,
the GAS motif) was more prominent in STAT3 peaks than
STAT1 peaks, particularly within peaks induced by both IL-6
and IL-27 (Figure 6C).
Next, we assessed STAT binding around differentially regu-
lated genes (Figure 6D, S5A, and Table S1). Comparable binding
of STAT3 and STAT1 was observed near genes that were regu-
lated by IL-6. However, STAT3 binding was reduced compared
to STAT1 near genes that were negatively regulated by IL-6,
possibly indicating a repressive effect of STAT1 for this category
of genes.
A major issue in STAT biology is the extent to which different
STATs can compensate for one another. This is especially the
case for STAT1 and STAT3 (Costa-Pereira et al., 2002; Qing
and Stark, 2004; Regis et al., 2008; Schiavone et al., 2011).
Therefore, we measured the binding of STAT1 and STAT3 in
the presence and absence of the opposing STAT. Consistent
with the asymmetric impact of each STAT deletion on transcrip-
tome, we found that genome-wide STAT3 binding increased in
Stat1/ cells, whereas STAT1 binding was significantly dimin-
ished in Stat3/ cells (Figure S5B). This latter effect was quite
evident for both IL-6 unique and commonly regulated genes (Fig-
ure 6D, left and middle panels). However, for IL-27 uniquely
regulated genes, STAT1 binding was relatively preserved in
Stat3/ cells, indicating a contribution of STAT1 independent
of STAT3 (Figure 6D, right panel). For genes whose cytokine
specificity was altered in the absence of one STAT, STAT3 bind-
ing showed compensatory increase in the absence of STAT1,
while STAT1 binding showed various degree of loss in the
absence of STAT3 (Figure S5A). The functional consequences
of this effect were confirmed by measuring IFN-g and RORgt
protein amounts. (Figure S5C and S5D). Overall STAT1 preferen-
tial binding and influence become more evident when a definedImmunity 42, 877–889, May 19, 2015 ª2015 Elsevier Inc. 881
IL-27 Unique genes (311):
A
Wild type Stat1-/- Stat3-/-
C
E
B
D
F
STAT1 regulated genes STAT3 regulated genes
STAT1 regulated genes STAT3 regulated genes
STAT1 regulated genes STAT3 regulated genes
90.1%
76.8%
74.9%
20.3%
20.6%
65.0%
IL-6 Unique genes (503):
Common genes (379):
IL-27 Unique genes (311):
Common genes (379):
Wild type Stat1-/- Stat3-/-
IL-6 IL-27 IL-6 IL-27 IL-6 IL-27
IL-27 IL-27 IL-27
IL-6 Unique genes (503):
Wild type Stat1-/- Stat3-/-
IL-6 IL-6 IL-6
Stimulation:
Stimulation:
Stimulation:
IL-6 Unique
IL-27 Unique
Common
H
Stat3-/-
Wild type 
0 1200600
Absolute gene numbers
13.6%
(42)
IL-27 Unique genes (311):
51.4%
(160)
25.4%
(79)
9.6%
(30)
STAT1 regulated, STAT3 unregulated
STAT1 unregulated, STAT3 regulated 
Both STAT1 and STAT3 unregulated
Both STAT1 and STAT3 regulated 
G
-2 20
-2 20
-2 20
Figure 3. STAT3 Controls the Magnitude of Transcriptional Output Induced by Both IL-6 and IL-27
Naive CD4+ T cells from wild-type, Stat1/, or Stat3/mice were cultured on anti-CD3- and anti-CD28-coated plates with or without IL-6 or IL-27 for 3 days.
RNA was isolated and global gene expression was determined by RNA-seq.
(A, C, and E) Groups of cytokine-responsive genes were selected as in Figure 1. Fold changes in expression of genes selectively regulated by IL-6 (A) (n = 503
genes) and IL-27 (E) (n = 311 genes) or both cytokines (C), n = 379 genes) in wild-type, STAT1/, or STAT3/ CD4+ T cells are shown by heatmaps.
(B, D, and F) STAT dependency was evaluated based on the loss of gene regulation in Stat1/ or Stat3/ CD4+ T cells and is depicted by pie charts.
(G) Contribution of STAT1, STAT3, or both in controlling genes selectively regulated by IL-27.
(H) Consequence of absence of STAT3 in mouse CD4+ T cells on genes regulated by IL-6 (blue), IL-27 (orange), and both cytokines (green). See also Figure S3.
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Figure 4. STAT1 Controls the Diversity of
Cytokine Responses Mediated by IL-6 and
IL-27
Wild-type and STAT1-deficient naive CD4+ T cells
were activated and cultured with cytokines.
(A) A total of 1,193 genes regulated by IL-6 (blue)
or IL-27 (orange) in wild-type cells and their over-
lap in STAT1/ cells are depicted.
(B) The number of genes regulated by IL-6 or IL-27
was increased in Stat1/ cells. These genes were
further classified into subgroups based on their
overlapping or unique cytokine response. Many
genes acquired cytokine response, indicative of
de novo gene regulation in Stat1/ (green and
dark orange).
(C) Genes regulated by IL-6 (blue), IL-27 (orange),
both (green), or neither (gray) are identified and
color-coded. The scatterplots are drawn to eval-
uate the similarity of gene expression between
IL-6 (x axis) and IL-27 (y axis) and the corre-
lation coefficient (r) was calculated. See also Fig-
ure S4.subgroup of genes was evaluated, namely IL-6 downregulated
or IL-27 uniquely regulated genes.
Given that STAT1 and STAT3 can form homo- and hetero-
dimers, we sought to investigate the possible generation of
such complexes by examining regions in which binding
of two STATs coincide or not. To quantify the likelihood of
homo- and hetero-dimer binding, we calculated the ratio
of STAT1 and STAT3 signals at peak locations and segregated
them into three bins according to the three possible STAT1
and STAT3 configurations. Peak locations were also linked
to the nearest genes as possible target of regulation (Fig-
ure 6E). In total, we observed 1.7-fold more STAT3 peaks
than STAT1 peaks genome wide. Of these, 33% of STAT3
peaks overlap with 56% of STAT1 peaks (Figure 6E, Venn
diagram). Across all cytokine-inducible genes, the fraction
of potential STAT3-STAT3 homodimers predominated. By
contrast, there were relatively few regions bound only by
STAT1. Notably, these were most often found that were in
proximity to IL-6 downregulated genes. These findings support
the idea that STAT3 dominantly regulates cytokine responsive
genes by working both singly (homodimers) and cooperatively
(heterodimers).Immunity 42, 877–8Human STAT1 Gain-of-Function
Mutation Leads to Aberrant
Transcriptome Profiles
Gain-of-function (GOF) STAT1 mutations
are associated with a rare primary immu-
nodeficiency with fungal infections (van
de Veerdonk et al., 2011). We used
T cells from these patients as a model
to evaluate the impact of mutant STAT1
on transcriptomes regulated by IL-27
and IL-6 (Table S2). Compared to con-
trols, T cells from STAT1 GOF patients
all exhibited a marked expansion of cyto-
kine inducible genes (Figure 7A). There
was a trend in the expansion of IL-6 regu-lated genes and a significant increase in IL-27-regulated genes
in the patient group (Figure 7B). Accordingly, the correlation
coefficient between IL-6 and IL-27 responsive genes was signif-
icantly reduced in T cells from patients with STAT1 GOF muta-
tions (Figure 7C). Many of the genes affected by STAT1 GOF
mutations were immunologically relevant, and thus likely
contribute to the pathologies associated with this genetic muta-
tion (Tables S3 and S4). Taken together, these findings are
consistent with the idea that STAT1 contributes to transcrip-
tomic diversity in response to cytokines.
DISCUSSION
Cytokines comprise a diverse group of factors such as interleu-
kins, interferons, and colony stimulating factors, as well as
classic hormones including growth hormone, erythropoietin,
and prolactin. Understanding the redundant and specific actions
of cytokines has been amajor challenge in the field. In this study,
we focused on two cytokines, IL-6 and IL-27, which share a re-
ceptor subunit (GP130) and two downstream signaling mole-
cules (STAT1 and STAT3) but have distinct biological actions.
Using genomic approaches, we generated a comprehensive89, May 19, 2015 ª2015 Elsevier Inc. 883
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Figure 5. Asymmetric Contribution of
STAT3 and STAT1 in Driving Magnitude
and Specificity of GP130 Cytokine Re-
sponses
(A and B) Circos visualization depicts the conse-
quence of absence of STAT1 (A) or STAT3 (B)
on cytokine regulated gene-expression change.
Cytokine response of genes is color coded as
IL-6 unique (blue), common (green), or IL-27
unique (orange) subgroups. Genes in wild-type
cells are aligned on the left side of the plots, and
the genes in STAT-deficient cells are aligned on
the right side of the plots with each connecting line
link the same gene on left and right. The color of
the connecting lines represents cytokine speci-
ficity of STAT-deficient cells. The genes that lost
cytokine responsiveness in Stat1/ or Stat3/
are shown in gray lines on the right half of the circle
without connecting lines. Many IL-6 unique or IL-
27 unique genes in wild-type switched to common
genes in Stat1/. Notable fraction of IL-6 unique
or common genes in wild-type became IL-27
unique genes in Stat3/.
(C) Principal-component analysis of the global
gene expression is shown as clusters are grouped
by genotype (wild-type, Stat1/, Stat3/). A total
of 18 samples (9 conditions in duplicate) of RNA-
seq data were plotted. The three main principal
components in the model contribute to explain
30.7%, 14.5%, and 9.13% of the variation,
respectively, and are predictive.
(D) The relative numbers of genes regulated by
IL-6 (blue), IL-27 (orange), or both cytokines
(green) are depicted as areas of the different
rectangles in mosaic plots for the indicated time
points.view of the action of these highly related cytokines and examined
the role of STATs in forming the distinctive transcriptomes.
A major goal of our study was to understand molecular under-
pinning to define specificity and redundancy of cytokine
response through the action of STAT proteins. STAT family884 Immunity 42, 877–889, May 19, 2015 ª2015 Elsevier Inc.molecules are evolutionally conserved
across a diverse range of organisms
and expanded during evolution along
with robust expansion of upstream cyto-
kine receptors after the emergence of
adaptive immunity (Gorissen et al.,
2011; Liongue et al., 2012). There are
seven mammalian STATs and circum-
stances in which a given cytokine can
be strongly linked to a particular STAT;
such is the case of IL-12 and STAT4 (Ka-
plan et al., 1996; Levy and Darnell, 2002;
O’Shea et al., 2002). From this perspec-
tive, IL-6 has often been equated with
STAT3 and IL-27 with STAT1 (Takeda
et al., 2003; Takeda et al., 1998). How-
ever, there are more than 60 cytokines
that signal via 7 STATs and the mismatch
in numbers means that many cytokines
activate the same STATs and the actionof cytokines likely represents the combinatorial engagement of
multiple STATs.
The notion that access to different STATs influences the
outcome of cytokine signaling has been articulated previously.
One view is that in the absence of its preferred STAT, a given
cytokine will acquire an alternative program through other STATs
(Costa-Pereira et al., 2002). Indeed, IL-6 can regulate selected
STAT1-inducible genes in STAT3-deficient cells (Costa-Pereira
et al., 2002). Based on these findings, it might be predicted
that in the absence of STAT3, IL-6 would approximate the action
of IL-27 through activation of STAT1. Although this might be true
for a subset of genes, our data clearly show that it is not the case
on the genome-wide scale. Rather, our data indicate that STAT3
is the engine that drives transcriptional outputs of both cyto-
kines, and it cannot be substituted by STAT1. Instead the major
function of STAT1 is to provide the specificity that distinguishes
IL-27 and IL-6. Our findings clearly demonstrate asymmetric
roles for STAT3 and STAT1 and therefore differ substantially
from previous views in which STAT1 and STAT3 were consid-
ered to have compensatory or overlapping roles (Costa-Pereira
et al., 2002; Qing and Stark, 2004; Regis et al., 2008; Schiavone
et al., 2011).
Our findings on the genome-wide distribution of STATs are
consistent with this asymmetric view. STAT3 occupies a
wider region of chromatin than STAT1, often as homodimers
and also likely in cooperation with STAT1 as heterodimers.
An unanticipated finding was the collapse of global STAT1
binding in the absence of STAT3. Interestingly, the few
remaining STAT1 bound regions present in the absence of
STAT3 occur in proximity to genes selectively regulated by
IL-27 or genes downregulated by IL-6, thereby contributing
to the specificity of IL-6 and IL-27 action. Because ChIP-seq
relies on the efficiency of any given antibody, we cannot
make definitive conclusions about the absolute numbers of
genomic STAT3 versus STAT1 binding sites. However the
dominance of STAT3 peaks over STAT1 peaks is entirely
consistent with the transcriptomic impact of loss of STAT3
versus STAT1.
The distinctive modes of action of STAT3 and STAT1 might
reflect evolution of cytokine pathways. GP130 is considered
as a primordial receptor subunit, with homologs present in
species such as tunicates and insects. In contrast, IL-27
appears to have arisen more recently during the evolution
in Euteleostomes, along with other components of the ver-
tebrate immune system. It is tempting to speculate that
newer cytokines like IL-27 commandeered existing scaffolds
(GP130) and achieve selectivity by engaging an additional re-
ceptor, in this case IL-27RA (WSX-1), which permits increased
access to STAT1. This would explain why the absence of
STAT3 cripples both IL-6 and IL-27 signaling and why STAT1
is the major driver of specificity. Previous reports support the
notion that cytokine receptors can access more than one
STAT protein and that this can be the mechanism by which
output can be dynamically controlled. For instance, the priming
of macrophages with IFN-g resulted in increased STAT1
expression, thereby altering the cytokine response (Hu et al.,
2002; Qiao et al., 2013). Likewise, the dynamic balance be-
tween STAT4 and STAT1 is crucial in modulating the course
of type I interferon responses during viral infection in T and
NK cells (Gil et al., 2012; Miyagi et al., 2007). Our findings using
cells from patients with STAT1 GOF mutations are in line with
these findings by showing that altering the balance between
STAT3 and STAT1 leads to global alteration in cytokine
response.Obviously, there are other factors that contribute to the spe-
cific of cytokine action. One is the duration of STAT signaling,
and factors attenuate STAT activation such as suppressor of
cytokine signaling (SOCS) proteins (Whitmarsh et al., 2011;
Yasukawa et al., 2003). We observed that IL-27 preferentially
induced SOCS1, whereas IL-6 preferentially induced SOCS3
(data not shown). Deletion of STAT1 abrogated IL-27 preferential
SOCS1 induction while SOCS3 induction was heavily STAT3
dependent (data not shown). Therefore, regulation of SOCS
expression is undoubtedly an additional factor that might
contribute to the distinctive cytokine signatures.
The other important factor to consider with respect to dura-
tion of signaling is the contribution of cytokines produced
secondarily, following the initial cytokine stimulation. For
instance, IL-27 induces the production of IFN-g, which en-
hances STAT1 activation (Villarino et al., 2003), whereas IL-6 in-
duces IL-21, which promotes phosphorylation of STAT3 (Suto
et al., 2008). Clearly, there might be many other factors aside
from these two cytokines that might be relevant with respect
to the induction of transcriptomes. More studies will be needed
to evaluate the range of factors produced in an autocrine
manner that contribute to the final output of cell signaling. On
a similar note, it will also be interesting to examine the effect
of other factors that engage STAT1 and assess the function of
STAT1 as a driver of cytokine specificity for these factors. For
example, it will be interesting to compare and contrast effect
of type I and type II IFNs with that of IL-27 in terms of cyto-
kine-specific transcriptomic signatures.
In summary, our study provides a quantitative and qualitative
evaluation of transcriptional programs elicited by two cytokines
that employ highly overlapping signaling pathways and eluci-
dates the molecular basis driving those transcriptome profiles.
Despite shared signal mechanisms, the actions of these related
cytokines can be remarkably distinct due to combinatorial and
asymmetric action of STATs to transcriptomic output and cyto-
kine diversity.
EXPERIMENTAL PROCEDURES
Mice
C57BL/6J were purchased from Jackson Laboratory and Stat3fl/fl mice were
from D. Levy (Lee et al., 2002) and bred with CD4-Cre+ Tg mice. Stat1/
mice were also from D. Levy (Durbin et al., 1996). All animal studies were per-
formed according to the National Institutes of Health (NIH) guidelines for the
use and care of live animals and were approved by the Institutional Animal
Care and Use Committee of NIAMS.
Naive CD4+ T Cell Isolation
CD4+ T cells from spleens and lymph nodes of 6- to 8-week-old mice were pu-
rified by negative selection and magnetic separation (Miltenyi Biotec) followed
by sorting of naive CD4+CD62L+CD44CD25 population using FACSAria II
(BD). See Supplemental Experimental Procedures for in vitro culture condition
and flow cytometry.
Immunoblotting
Cells were lysed in Triton X-100 lysis buffer containing protease inhibitors.
Equal amounts of total protein were separated by PAGE, transferred to nitro-
cellulose, and blotted with antibodies recognizing actin (Millipore), STAT1
(#9172), or STAT3 (#4904) (both from Cell Signaling Technology). Secondary
antibodies conjugated with IRDye800 (Rockland) or Alexa Fluor 680 (Invitro-
gen) were used for detection, and specific bands were visualized using an
Odyssey infrared imaging system (LI-COR Biosciences).Immunity 42, 877–889, May 19, 2015 ª2015 Elsevier Inc. 885
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Figure 6. STAT1 Binding to Chromatin Is Largely STAT3 Dependent
(A) STAT1 (right) and STAT3 (left) binding was assessed by ChIP-seq and clustered into seven categories based on cytokine response to IL-6 and IL-27 as
indicated.
(B) Proportions of peaks segregating into the clusters shown in (A) were shown for STAT1 and STAT3.
(legend continued on next page)
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A Figure 7. STAT1 Gain-of-Function Muta-
tions in Human CD4+ T Cells Exhibit
Enhanced Transcriptomic Output and Di-
versity in Response to IL-6 and IL-27
Sorted naive CD4+ T cells (CD4+CD45RA+) from
age- and sex-matched healthy control (HC) and
patients with STAT1 gain-of-function (STAT1
GOF) (Table S2) were stimulated with plate-coated
anti-CD3 and anti-CD28 with or without (un-
treated) IL-6 (50 ng ml1) or IL-27 (50 ng ml1) for
3 days. RNA was isolated and analyzed bymRNA-
Seq. (A) Genes whose expression was altered are
clustered based on their selective regulation by
IL-6 (blue), IL-27 (orange), or commonly (green)
by both cytokines in healthy control (HC) subjects
(n = 4) and STAT1 GOF patients (STAT1 GOF)
(n = 5). See Experimental Procedures (mosaic
plots) for details.
(B) The absolute number of cytokine regulated
genes was quantitated in healthy control subjects
(n = 4) and STAT1 GOF patients (n = 5) (mean ±
SEM, p value by unpaired Student’s t test, NS, not
significant).
(C) Similarities in IL-6 and IL-27-regulated genes
were quantitated (Pearson correlation coefficients,
mean ± SEM, p value by unpaired Student’s t test).
See also Tables S2 and S3.mRNA Sequencing
Total RNA was prepared from approximately 1 million cells by using mirVana
miRNA Isolation Kit (AM1560, ABI). A fraction of total RNA (200 ng) was pro-
cessed into mRNA-seq library by using TruSeq SR RNA sample prep kit
(FC-122-1001, Illumina). The libraries were sequenced for 50 cycles (single
read) with a HiSeq 2000 (Illumina). Raw sequencing data were processed
with CASAVA 1.8.2 to generate FastQ files, mapped onto the mouse genome
build mm9 using TopHat 2.0 (Trapnell and Salzberg, 2009), and gene expres-
sion values (RPKM, reads per kilobase exon per million mapped reads) were
calculated with Partek Genomics Suite 6.6. All downstream statistical ana-
lyses, including PCA, were performed with Partek Genomics Suite 6.6, R(C) Quantitation of STAT1 (blue) and STAT3 (red) peaks with or without a STAT-binding motif was shown for
(D) STAT3 (red) and STAT1 (blue) read countswithin 50 kb of TSS and TES of cytokine regulated genes in wild-t
in each group was shown in a parenthesis. See Experimental Procedures (stat binding box plots) for details.
(E) The numbers of overlapping and unique peaks bound by STAT1 and STAT3 are shown in Venn diagrams. T
determined by assessing the ratio of STAT3 and STAT1 signals and linked to the nearest gene. The STAT peak
of the nearest genes. STAT1 and STAT3 ChIP-Seq experiments were done two times under similar conditio
Immunity 42, 877–83.0.1, and GeneSpring GX 12.1 (Agilent Technolo-
gies). Differentially regulated genes were selected
with following criteria (1) absolute RPKM > 1 in at
least 1 condition (basal, IL-6-, or IL-27-stimula-
tion), and (2) expression change > 2 or < 2.
Gene Set Enrichment Analysis
Gene set enrichment analysis (GSEA) from the
Broad Institute (http://www.broad.mit.edu/gsea)
was used. Th1, Th2, and Th17 cell-associated
gene sets were previously published (Roychoud-
huri et al., 2013; GEO GSE45975).
EMSA
EMSAswere performed usingGel Shift Assay Sys-
tems (Promega). Nuclear extracts were prepared
from cultured T cells and incubated at 4C with
32P-labeled double-stranded oligo (STAT oligo;GATCCGGGAGGGATTTACGGGAAATGCTG) in DNA binding buffer. Electro-
phoresis was performed on a 4% native polyacrylamide gel (0.5 3 TBE;
acrylamide/bisacrylamide, 29:1), and the radioactivity was visualized by
autoradiography.
Circos
We used Circos (Krzywinski et al., 2009) plots to generate Figures 5A and 5B.
Mosaic Plots
R 3.0.1 was used to generate mosaic plots. For human data sets, cytokine
response of each gene was determined and classified into three groupsseven categories.
ype and STAT-deficient cells. The number of genes
(*p < 0.05, NS, not significant).
he potential distinct STAT dimer composition was
s were then sorted based on the cytokine response
ns. See also Figure S5 and Table S1.
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(IL-6 unique, IL-27 unique, or common) as follows: (1) absolute RPKM > 1 in
at least 1 condition (basal, IL-6-, or IL-27-stimulation); (2) expression fold
change > 2 or < 2 by cytokine. Once each gene of each individual was clas-
sified for its cytokine specificity, the second round of evaluation was done as a
group (healthy control and patient groups separately); (3) IL-6 (or IL-27) unique
genes are genes for which in at least one subject showed IL-6 (or IL-27) unique
response and other subjects were either no response or IL-6 unique; or (4)
common genes were genes that did not meet the criteria (3).
Human Naive CD4+ T Cell Isolation
All samples were collected under approved NIH protocols; all patients or their
parents provided written informed consent. Peripheral blood mononuclear
cells were prepared from venous blood by Ficoll-gradient centrifugation. Naive
CD4+CD45RAhighCD45ROlow population was purified by the flow cytometry
using FACSAria II (BD). See Supplemental Experimental Procedures for
in vitro cell culture conditions.
Chromatin Immunoprecipitation
Cells cultured as indicated were cross-linked for 10min with 1% formaldehyde
and harvested. Cells were lysed by sonication and immunoprecipitated with
indicated antibodies (STAT1 [sc-592, Santa Cruz Biotechnology] or STAT3
[14-6727-81 eBioscience]). Recovered DNA fragments were blunt-end ligated
to the Illumina adaptors, amplified, and sequenced by using the Hi-Seq 2000
(Illumina). Reads of 50 bases were aligned to the mouse genome build mm9
with Bowtie 0.12.8 (Langmead et al., 2009), allowing two mismatches.
Uniquely mapped and non-redundant reads were used for peak calling using
MACS 1.4.2 (Zhang et al., 2008) with a p value < 1.0E-05.
STAT Binding Box Plots
Following peak calling by MACS 1.4.2, PAPST (Bible et al., 2015) was used to
calculate the combined peak reads (normalized to per million) within extended
gene body (RefGene, from [TSS-50k] to [TTS+50k]). The log2 transformed gene
body readswere used tocreateboxplots, eachwithdatacorresponding to aset
of genes of interest under a specific biological condition. The log2 transformed
read data for boxplots were also used for p value calculations using Welch’s
t test. Both box plots and p values (Table S1) were generated using R.
Statistics
For statistical analysis, Student’s t test was used unless otherwise specified to
calculate statistical significance of the difference in mean values and p values.
For calculation of correlation coefficient, Pearson’s correlation was used.
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